Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
作者信息
Chadwick Christopher, Friede Martin, Moen Ann, Nannei Claudia, Sparrow Erin
机构信息
The World Health Organization, Geneva, Switzerland.
The World Health Organization, Geneva, Switzerland.
出版信息
Vaccine. 2022 Aug 5;40(33):4673-4675. doi: 10.1016/j.vaccine.2022.06.057. Epub 2022 Jul 7.
Abstract
摘要
相似文献
1
Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.流感疫苗技术转让计划——借鉴过去，启迪未来。
Vaccine. 2022 Aug 5;40(33):4673-4675. doi: 10.1016/j.vaccine.2022.06.057. Epub 2022 Jul 7.
2
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.罗马尼亚大流行性流感疫苗生产水包油乳剂佐剂制造技术转让：含佐剂裂解病毒灭活H5N1疫苗的临床前评估
Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.
3
A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).十年适应期：世界卫生组织对《全球流感疫苗行动计划（2006 - 2016）》的监管贡献
Vaccine. 2016 Oct 26;34(45):5414-5419. doi: 10.1016/j.vaccine.2016.07.025. Epub 2016 Aug 3.
4
Preparing for a possible pandemic: influenza A/H5N1 vaccine development.为可能的大流行做准备：甲型H5N1流感疫苗的研发。
Curr Opin Pharmacol. 2007 Oct;7(5):484-90. doi: 10.1016/j.coph.2007.06.004. Epub 2007 Jul 17.
5
Designing vaccines for pandemic influenza.设计大流行性流感疫苗。
Curr Top Microbiol Immunol. 2009;333:165-76. doi: 10.1007/978-3-540-92165-3_8.
6
Avian influenza vaccines against H5N1 'bird flu'.针对 H5N1“禽流感”的禽流感疫苗。
Trends Biotechnol. 2014 Mar;32(3):147-56. doi: 10.1016/j.tibtech.2014.01.001. Epub 2014 Feb 1.
7
Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season.2007 - 2008流感季节使用的流感病毒疫苗推荐成分。
Wkly Epidemiol Rec. 2007 Mar 2;82(9):69-74.
8
Strategies for developing vaccines against H5N1 influenza A viruses.研发抗H5N1甲型流感病毒疫苗的策略。
Trends Mol Med. 2006 Nov;12(11):506-14. doi: 10.1016/j.molmed.2006.09.003. Epub 2006 Sep 29.
9
Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.针对 H5N1 流感爆发开发减毒活流感疫苗。
Viruses. 2012 Dec 10;4(12):3589-605. doi: 10.3390/v4123589.
10
Recommended composition of influenza virus vaccines for use in the 2008 influenza season.2008年流感季节使用的流感病毒疫苗推荐成分。
Wkly Epidemiol Rec. 2007 Oct 5;82(40):351-6.
引用本文的文献
1
Global production capacity of seasonal and pandemic influenza vaccines in 2023.2023年季节性流感疫苗和大流行流感疫苗的全球生产能力。
Vaccine. 2025 Apr 2;51:126839. doi: 10.1016/j.vaccine.2025.126839. Epub 2025 Feb 18.
2
'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.“我们的项目，你的问题？” 世界卫生组织在南非的信使核糖核酸技术转让计划案例研究
PLOS Glob Public Health. 2024 Sep 23;4(9):e0003173. doi: 10.1371/journal.pgph.0003173. eCollection 2024.
3
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries.在低收入和中等收入国家实现单克隆抗体公平可及的新方法。
PLOS Glob Public Health. 2024 Jul 1;4(7):e0003418. doi: 10.1371/journal.pgph.0003418. eCollection 2024.
4
Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond.中低收入国家单克隆抗体面临的临床和监管挑战与机遇：COVID-19 及其他方面的经验教训。
Pharmaceut Med. 2023 May;37(3):203-214. doi: 10.1007/s40290-023-00473-z. Epub 2023 Apr 28.
本文引用的文献
1
Global production capacity of seasonal and pandemic influenza vaccines in 2019.2019年季节性流感疫苗和大流行性流感疫苗的全球生产能力。
Vaccine. 2021 Jan 15;39(3):512-520. doi: 10.1016/j.vaccine.2020.12.018. Epub 2020 Dec 16.
2
Considerations for sustainable influenza vaccine production in developing countries.发展中国家可持续流感疫苗生产的考量因素。
Vaccine. 2016 Oct 26;34(45):5425-5429. doi: 10.1016/j.vaccine.2016.08.056. Epub 2016 Sep 7.
3
Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative.世卫组织流感疫苗技术转让倡议的受助方及技术咨询小组所面临的挑战与取得的成功
Vaccine. 2016 Oct 26;34(45):5420-5424. doi: 10.1016/j.vaccine.2016.07.047. Epub 2016 Aug 6.
4
Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.为流感疫苗制造商提供化学、生产和控制（CMC）及临床试验技术支持。
Vaccine. 2016 Oct 26;34(45):5430-5435. doi: 10.1016/j.vaccine.2016.07.046. Epub 2016 Jul 30.
5
Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development.流感疫苗生产综合实践培训：世卫组织、美国生物医学高级研究与发展局和生物医学培训与教育中心为全球劳动力发展建立的伙伴关系。
Biochem Mol Biol Educ. 2014 Sep-Oct;42(5):414-9. doi: 10.1002/bmb.20817. Epub 2014 Aug 18.
6
Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program.疫苗生产培训，以培养 BARDA 流感疫苗能力建设计划支持的外国机构的劳动力。
Vaccine. 2013 Mar 15;31(12):1646-9. doi: 10.1016/j.vaccine.2012.06.041. Epub 2012 Jun 29.
7
An international technology platform for influenza vaccines.流感疫苗国际技术平台。
Vaccine. 2011 Jul 1;29 Suppl 1:A8-11. doi: 10.1016/j.vaccine.2011.04.124.
8
The Vaccine Formulation Laboratory: a platform for access to adjuvants.疫苗制剂实验室：一种获取佐剂的平台。
Vaccine. 2011 Jul 1;29 Suppl 1:A37-9. doi: 10.1016/j.vaccine.2011.04.125.
9
WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.世卫组织倡议在大流行时增加全球和公平获得流感疫苗的机会：通过技术转让支持发展中国家的生产能力。
Vaccine. 2011 Jul 1;29 Suppl 1:A2-7. doi: 10.1016/j.vaccine.2011.02.079.
Zotero 插件